Caramont 10Mg

COMPOSITION

Each Film Coated Tablet Contains Montelukast Sodium Equivalent to Montelukast 5mg. Each Film Coated Tablet Contains Montelukast Sodium Equivalent to Montelukast 10mg. Each Chewable Tablet Contains Montelukast Sodium Equivalent to Montelukast 5mg. 

DESCRIPTION

CARAMONT (Montelukast Sodium) is a selective leukotriene receptor antagonist. It is a specific inhibitor of the cysteinyl leukotriene CysLT, receptor. 

INDICATIONS

Prophylaxis & treatment of chronic asthma in pediatric & adult patients. Prevention of symptoms & treatment of aspirin sensitive asthmatic patients. Prevention of exercise induced bronchoconstriction. Prevention & treatment of severe allergic rhinitis. 

SIDE EFFECTS

Montelukast is generally well tolerated. The overall incidence of reported side effects is comparable to placebo. The following adverse effects have been reported hypersensitivity reactions (anaphylaxis, rash, pruritis, urticaria, angioedema) restlessness, drowsiness, nausea, vomiting, insomnia and diarrhea.  

CONTRAINDICATIONS

Hypersensitivity to any ingredients. 

WARNING & PRECAUTIONS

The efficacy of oral CARAMONT has not been established for the treatment of acute asthma, therefore. CARAMONT should not be used orally to treat acute asthma attacks, patients should be properly advised to have appropriate rescue medication. 

OVERDOSAGE

No data is available on treatment of over dosage with montelukast. However, in the event of an over dosage gastric lavage and general supportive measures should be taken. It is unknown whether montelukast is dialyzable by peritoneal or hemodialysis. Risk of Neuropsychiatric reactions: Healthcare professionals are advised to be alert for neuropsychiatric reactions, including changes in behavior, speech impairment, depression and obsessive-compulsive symptoms, in adults, adolescents and children taking montelukast. The risks and benefits of continuing treatment should be evaluated if these reactions occur. Patients should be advised to read the list of neuropsychiatric reactions in the product information leaflet and seek immediate medical attention if they occur. Information for the Patients/Care giver: What should patients and parents/care givers do? Patients and parents/care givers should stop montelukast and discuss with a health are professional right away if you or your child experience behavior or mood related changes while taking the medicine. These may include agitation, including aggressive behavior or hostility, attention problems, bad or vivid dreams, depression, disorientation or confusion, feeling anxious, hallucinations (seeing or hearing things that are not really there), irritability, memory problems, obsessive compulsive symptoms, restlessness, stuttering, sleep walking, suicidal thoughts and actions, tremor or shakiness, trouble sleeping, uncontrolled muscle movements. 

CARAWAY PHARMACEUTICALS